- Pharmaceutical companies
- Bracco
Bracco
Phone: +39 02 21771
On 1 July 1927, a small company trading in pharmaceuticals set up an office in Piazzale Susa in Milan. A few weeks earlier, Elio Bracco had signed a notary deed incorporating the company bearing his name, the company that is now the Bracco Group. The family business, which has never stopped growing since then, is now an established global leader in diagnostic imaging, an advanced medical technology that underpins a whole area of treatment vital for human health. The success of the Bracco Group is also ascribable to the far-sighted vision of the founder’s son, Fulvio, who joined his father’s firm immediately after graduating from Pavia University. In the 1950s, Fulvio focused his research activity on the chemistry of iodine and its use in diagnostic imaging, then a niche area of interest, which he developed into an industry that Bracco has been revolutionizing ever since.
The Group's main products are contrast media, medicinal specialities used to improve the diagnostic accuracy of biomedical imaging and the management of patients with diseases of various natures and severity.
For detailed contact information visit location pages below.
Bracco's locations around the world
Clinical Trials sponsored by Bracco
-
Bracco Diagnostics, IncBracco Imaging S.p.A.Completed
-
Bracco Diagnostics, IncBracco Imaging S.p.A.TerminatedProstate CancerItaly, Austria, France, Netherlands, Belgium, Germany, United Kingdom
-
Bracco Diagnostics, IncClinipace Worldwide; Bracco International B.V.CompletedPeripheral Artery Disease | Pulmonary Disease | Carotid Disease | Aortic DisordersChina
-
Bracco Diagnostics, IncCompletedSteno-occlusive DiseaseItaly
-
Bracco Diagnostics, IncCompletedProstate CancerUnited States, France
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
Bracco Diagnostics, IncCompleted
-
Bracco Diagnostics, IncCompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
Bracco Diagnostics, IncCompletedEvaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney DiseaseRenal InsufficiencyUnited States
-
Bracco Diagnostics, IncTerminated